secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orchard Therapeutics plc (—)
CIK:        0001748907
Form:       8-K
Filed at:   2024-01-24T23:59:59+00:00
Accession:  0001193125-24-014239
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orchard acquired by Kyowa Kirin for $16/ADS plus CVRs; delisted from Nasdaq
---------------------------------------------------------------------------

- Shareholders get $16.00 per ADS ($1.60 per share) plus 10 CVRs per ADS; each CVR pays $0.10 if FDA approves OTL-200 by Dec 31, 2024.
- Transaction closed Jan 24, 2024 after court sanction; Company becomes indirect wholly owned subsidiary of Kyowa Kirin.
- Nasdaq trading suspended; Company to file Form 25 to delist and Form 15 to suspend SEC reporting obligations.
- All prior board members resigned; new directors appointed: Takeyoshi Yamashita, Yasuo Fujii, Abdul Mullick.
- All outstanding debt under Senior Term Facilities Agreement repaid and credit commitments terminated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1748907/000119312524014239/0001193125-24-014239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1748907/000119312524014239/d74405d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-014239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer